Objective-To investigate whether several different measures of carotid intima-media thickness (IMT) progression are associated with subsequent vascular events and whether such associations are independent of baseline carotid atherosclerotic profile and Framingham risk factors. Approach and Results-A longitudinal cohort study (the Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population study) was performed in 7 centers in 5 European countries (Finland, France, Italy, the Netherlands, and Sweden). Three thousand four hundred eighty-two subjects (median age 64.1 years; 47.8% men) with ≥3 vascular risk factors were recruited and monitored for a postprogression median follow-up of 21.5 months, during which time 129 subjects experienced a first vascular event (incidence of 20.4 per 1000 person-years). The 15th month progression of mean and maximum carotid IMT of the left and right common carotids, bifurcations, internal carotid arteries, and their composite measures, as well as the fastest IMT max progression (Fastest-IMT max-progr ) detected in the whole carotid tree regardless of location, were used in statistical analyses. All carotid IMT measures showed significant progression during the first 15 months (P<0.001), but only the Fastest-IMT max-progr was significantly associated with the risk of subsequent vascular events. The Fastest-IMT max-progr association persisted after Bonferroni correction for multiple comparisons and after adjustments for Framingham risk factors and pharmacological treatments (all P<0.005). The use of Framingham Risk Score in place of Framingham risk factors provided almost identical results (P=0.003). Conclusions-The Fastest-IMT max-progr , a novel approach to assess carotid IMT progression, identifies focal increases of carotid IMT and, in contrast to other progression variables, is associated with cardiovascular risk. (Arterioscler Thromb Vasc Biol. 2013;33:2273-2279.) on behalf of the IMPROVE Study Group
C hanges in carotid-intima media thickness (C-IMT) over time have been increasingly used in interventional trials as a surrogate outcome measure of therapy. 1 However, although the 1-time measure of C-IMT is widely accepted as a reliable surrogate marker of subclinical atherosclerosis, [2] [3] [4] [5] the clinical relevance of changes in C-IMT over time is still unclear. Several studies have established that C-IMT changes over time (C-IMT progression or regression) are associated with vascular risk factors (VRFs) 6 and coronary atherosclerosis, 7 but studies assessing whether the rate of progression associates with an increased risk of vascular events (VEs) remain inconclusive. [8] [9] [10] [11] Another still unresolved issue is which of the carotid segments (eg, common carotid [CC], bifurcation [BIF] , or internal carotid arteries [ICA]) or which summary measure of C-IMT (mean, maximum, or mean of maximum) is best suited to reflect clinically relevant C-IMT progression. The observation that plaques preferentially occur at the level of the BIF and internal carotid arteries has suggested that C-IMT measurements at these sites better reflect true atherosclerosis than measures in the CC segment. 4, 12 Again, knowledge of how rates of C-IMT progression at different arterial sites relate to occurrence of VEs is limited.
To establish the significance of C-IMT progression as a surrogate measure of vascular risk, we conducted the IMPROVE study, a European prospective study whose primary objective was to assess whether C-IMT changes, measured at different carotid sites, associate with subsequent VEs, independently of the baseline atherosclerotic profile and Framingham risk factors.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Follow-Up and VEs
Starting from the 15-month visit, at which time any change in C-IMT was assessed, the median follow-up was 21.5 months (interquartile range, 20. 8-22.7) . Among the 3482 subjects included in the analysis, 129 (3.7%) developed a VE in the follow-up period: 15 had an acute myocardial infarction (0 fatal), 26 were hospitalized for angina pectoris, 24 underwent angioplasty, and 10 coronary bypass grafting. There were 2 sudden cardiac deaths, 21 had an ischemic stroke (0 fatal), 22 had a transitory ischemic attack, 2 underwent peripheral revascularization, and 7 had a new diagnosis of intermittent claudication. Twenty-one participants had >1 VE in the course of follow-up. The baseline characteristics of subjects with and without incident VEs are shown in Table 1 . Fewer than 10% of all subjects changed their medications during follow-up.
C-IMT Changes During the First 15 Months
Significant C-IMT progression was observed in all segments and all summary measures considered (Table 2; all P<0.0001). The increases in the conventional C-IMT variables were between 0.005 mm/y (CC-IMT mean ) and 0.049 mm/y (Bif-IMT max ), with the highest average progression occurring in BIFs and the lowest in CC arteries. The average Fastest-IMT max-progr (0.271 mm/y) was ≈23× greater than the average change in C-IMT mean and ≈7× greater than that of C-IMT max . Table 2 also shows that the error associated with the individual progression rate of classical C-IMT variables (SD of the replicated yearly progressions) was between 0.020 mm/y (CC-IMT mean ) and 0.136 mm/y (internal carotid arteries-IMT max ). Among conventional C-IMT variables, IMT mean-max was associated with the best signal/error ratio (0.45). The error associated with the estimate of the Fastest-IMT max-progr was 0.114 mm/y, and the signal-to-noise ratio was 2.26.
C-IMT Change and Risk of Subsequent VEs
In a Cox analysis (Table 3) , the only variable significantly associated with the risk of VEs was the Fastest-IMT max-progr (P<0.005 by test for trend). In all models, the percentage risk increase associated with a 1 SD (0.27 mm/y) change of the Fastest-IMT max-progr ranged from 25% to 29%. In contrast, all other segment-specific or summary measures of C-IMT progression showed nonsignificant association with VEs in all models, with hazard ratios (HRs) very close to 1 (none exceeding 1.12). Of note, HRs were almost identical in model 3 and model 4 (where Framingham Risk Score [FRS] was replaced with Framingham risk factors) and in model 5, in which diabetes mellitus and systolic blood pressure were replaced with their mean and change between the first and the second visit. The HR of the Fastest-IMT max-progr remained statistically significant by Bonferroni criteria (P<0.005) also after adjustment for mean and change of antihypertensive and lipid-lowering treatments (model 6) and for creatinine and hemoglobin concentrations (model 7; P=0.0037). Overall, 39 subjects were outliers in the change of systolic and diastolic blood pressure, high-density lipoprotein and low-density lipoprotein cholesterol, creatinine, hemoglobin, and education (study-years). Also after excluding these outliers, the HR (95% confidence interval [ CI]) of model 7 remained substantially unchanged (data not shown). The use of the mean C-IMT of the first and the second scan as covariate in place of baseline C-IMT produced substantially identical results (data not shown).When the Cox analysis adjusted for age, sex, and baseline, C-IMT was restricted to hard clinical events (n=38; 15 myocardial infarction, 21 stroke, and 2 sudden cardiac deaths), whereas no significant association was detected for almost all conventional progression variables. The HR for Fastest-IMT max-progr was substantially unchanged and significant: 1.35 (1.06-1.73); P=0.014.
The comparison of the McFadden pseudo r 2 associated with each progression variable ( Table III in the online-only Data Supplement) indicates that the contribution of several conventional progression variables is virtually zero and that the r 2 associated with the Fastest-IMT max-progr is more than twice that of the best performing variable (IMT max-progr ).
The time-dependent receiver operating characteristic curve analysis showed that, in contrast to all the other progression variables, the Fastest-IMT max-progr provided a significant (P=0.03) improvement in area under the curve with respect to CC-IMT mean-progr (Table IV in the online-only Data Supplement).
In a sensitivity analysis, by simulating a measurement error twice as big as the original one, the Fastest-IMT max-progr still remained a significant predictor of VEs (area under the curve=0.58; P=0.012; contrast versus CC-IMT mean-progr : P=0.068).
In reclassification analysis, comparing the Fastest-IMT max-progr with the conventional IMT progression variables, the Integrated Discrimination Improvement value was always positive, with P values <0.01 (Table V in the online-only Data Supplement). Figure 1 shows the Kaplan-Meier incidence curves adjusted for the same variables used in model 7 of Table 3 . After stratifying subjects into 4 groups according to IMT mean-max (mean of the first and the second scan) and Fastest-IMT max-progr above or below medians (1.36 mm and 0.175 mm/y, respectively), the additive effect was significant (P=0.04). No significant interaction (P=0.10) was found between IMT mean-max and the Fastest-IMT max-progr . 
Location of Fastest-IMT max-progr and Relationship With Plaques
The fastest progression was observed in the 1 st CC in 4.9% of subjects (4.5% in the left and 0.4% in the right), in the remaining part of CC in 20% of subjects (11.6% in the left and 8.3% in the right), in the BIF in 45.6% of subjects (22.8% in the left and 22.8% in the right), and in the internal carotid arteries in 29.5% of subjects (14.5% in the left and 15.1% in the right).
Even if a significant association between the Fastest-IMT max-progr and the baseline IMT value was observed (β=0.068; SE=0.008; P<0.0001, after adjustment for VRFs), it has to be underlined that Fastest-IMT max-progr does not mean and sex; model 2 adjusted for the baseline C-IMT in addition to age and sex. Model 3 included variables from model 2 and educational level (study years), lifelong occupation (in 3 levels: manual, service and office worker), and Framingham Risk Score (FRS). In Model 4, FRS was replaced with baseline Framingham risk factors (FRFs), excluding age and sex, that is, smoking status (never/former/current smoker), diabetes mellitus, systolic blood pressure, HDL and LDL cholesterol. In Model 5, diabetes mellitus and systolic blood pressure were replaced with their mean and change between the first and the second visit. Model 6 included variables from model 5 and mean and change of antihypertensive and lipid-lowering treatments. Model 7 included variables from model 6 and creatinine and hemoglobin concentrations. Because measurements of total and HDL cholesterol, as well as creatinine and hemoglobin concentrations, were not available at month 15, it was not possible to consider the mean and change for these variables; thus, only baseline values were used. To take into account the heterogeneity of C-IMT measurements among European centers, all models were also stratified by latitude. In all models, outliers (±7 SD) were excluded. BIF indicates bifurcation; CC, common carotid; CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; ICA, internal carotid artery; IMT, intima-media thickness; and LDL, low-density lipoprotein. *P<0.005 (threshold according to Bonferroni correction for 10 comparisons).
progression of the biggest plaque at baseline. In fact, we selected the segment with the Fastest-IMT max-progr in all subjects, even in those without any plaque at baseline (31.5%). In addition, the carotid segment presenting the Fastest-IMT max-progr had the greatest baseline C-IMT in <20% of the subjects, and in only 36.4% of the patients with ≥1 plaque at baseline, the segment presenting the Fastest-IMT max-progr had a plaque. Finally, in Cox analyses adjusted for age, sex, and baseline atherosclerotic profile, the Fastest-IMT max-progr predicted VEs not only in subjects with plaques at baseline (HR for 1 SD increase of Fastest-IMT max-progr 1.33 [95% CI, 1.05-1.69; P=0.017]), but also in those without (HR for 1 SD increase of Fastest-IMT max-progr 1.29 [95% CI, 1.12-1.48; P=0.0005]).
Baseline Characteristics Stratified by Tertiles of Fastest-IMT max-progr
The baseline characteristics of participants, stratified by tertiles of Fastest-IMT max-progr , are shown in Table VI in the online-only Data Supplement. With some exceptions, a significant trend according to tertiles was found for most anthropometric and biochemical variables, VRFs and FRS, with participants in the highest tertile of Fastest-IMT max-progr having a more proatherogenic profile than subjects in the middle and lowest tertiles.
Clinical Value of the Fastest-IMT max-progr
To assess whether the Fastest-IMT max-progr can be used to monitor the response to therapy, 1138 subjects, who reported to be treated with statins in ≥1 visit, were 1:1 matched for FRS with subjects who were statin-naive at all visits (Figure 2) . The statin-treated subgroup was then stratified in fast progressors and slow progressors (ie, subjects with a Fastest-IMT max-progr above [n=557] or below [n=581] the median [0.21 mm/y], respectively) and compared with statin-naive subjects by Cox analyses. The incidence of VEs in fast progressors was twice as greater than that of slow progressors (HR, 2.16; 95% CI, 1.02-4.55; P=0.043) but was practically identical to that of statin-naive subjects (HR, 1.04; 95% CI, 0.63-1.71; P=0.89).
Sex Differences
Men and women differed in mean values for many baseline variables (data not shown), but no significant interactions with sex were found in any of the analysis presented.
Discussion
In the present study performed in European individuals with ≥3 VRFs, all C-IMT measurements progressed significantly during the fairly short period of 15 months, albeit at different rates, although a large proportion of subjects (>46%) were treated with antiatherosclerotic drugs. Thus, even in the era of effective antiatherosclerotic treatments, a relatively short time is sufficient to detect significant changes in C-IMT that may be of clinical importance. To date, 3 studies 8-10 have reported significant relationships between C-IMT progression and risk of coronary VEs 8, 9 or cerebro VEs. 10 Conversely, a recent meta-analysis of 16 general population studies (36 984 participants) failed to reveal any significant relationship. 11 In our study, we also failed to detect significant associations between C-IMT progression variables and VEs, with the exception of the newly devised Fastest-IMT max-progr variable, which, thus, may represent a better surrogate measure of vascular risk than any other Figure 1 . Additive effect of baseline intima media thickness (IMT) mean-max and Fastest-IMT max-progr assessed by stratifying the study population into 4 groups according to IMT mean-max (mean of the first and the second scan) and Fastest-IMT max-progr values above (high) or below (low) the medians (1.36 mm and 0.175 mm/y, respectively).
0.0% 0.5% single-segment or composite C-IMT progression variable considered to date. This may seem surprising because the Fastest-IMT max-progr , being the maximum value of a distribution, should be affected by a higher variability and a more skewed distribution than conventional variables. Instead, it is notable that the Fastest-IMT max-progr was ≥5× greater than any other C-IMT progression variable, with no greater variability: the SD of the Fastest-IMT max-progr was of the same order of magnitude as the SDs of IMT max progression variables. Thus, the signal-to-noise ratio associated with the Fastest-IMT max-progr was ≈5× greater than that of any of the conventional variables, with consequent increase in statistical power. The Fastest-IMT max-progr was not only the unique variable significantly associated with VEs but also a better predictor of VEs than any conventional progression variable, in terms of model fitting, of receiver operating characteristic curve analysis and of reclassification. The Fastest-IMT max-progr remained a significant predictor of VEs even doubling the measurement error.
A possible explanation for this better performance of the Fastest-IMT max-progr is that it reflects, better than any other IMT measures, the underlying focal increases in wall thickness related to VEs. The progression models based on mean values (ie, IMT mean-progr , IMT mean-max-progr ) erroneously assume C-IMT progression to be evenly distributed throughout the carotid tree and, as such, tend to dilute the true focal effect. Conversely, segment-specific progressions, although in line with a model of focal progression, tend to include both progressing and nonprogressing areas (because the focal progression may occur in different segments in different individuals), thus diluting the fastest focal change and increasing the variability.
It has been reported that progression of carotid total plaque area predicts VEs 13 and that total plaque area, measured at baseline, more strongly predicts myocardial infarction 14 and stroke 15 than IMT. A recent meta-analysis confirmed these observations by showing that carotid plaque, compared with C-IMT, more accurately predicts future VEs. 16 The same metaanalysis, however, also showed that C-IMT measurement had a greater diagnostic accuracy than plaques when the measurements comprised not only the CC, but also the bifurcation and the internal carotid artery, where plaques are more prevalent, thus suggesting that it is essential to incorporate plaques in IMT measurements. On this basis, one can argue that the Fastest-IMT max-progr is nothing else than an index of the progression of plaque thickness. Of note, we found that Fastest-IMT max-progr occurs in segments with a pre-existing plaque only in approximately one third of subjects and that this variable predicts VEs both in subjects with plaques at baseline and in those without. As such, the Fastest-IMT max-progr is not simply a measure of plaque-thickness progression. Interestingly, the association of Fastest-IMT max-progr with VEs remained significant after adjustment for multiple confounders and baseline C-IMT, which suggests that this newly identified variable provides information over and above baseline VRFs, baseline FRS, and the initial atherosclerosis profile and can be used to define an individual's residual cardiovascular risk. This concept is supported by the highest estimated cumulative incidence of VEs observed among subjects having both an increased IMT mean-max (mean of the first and the second scan) and an increased Fastest-IMT max-progr (Figure 1 ). Last but not least, the Fastest-IMT max-progr allows identification of those patients who, being fast progressors despite their treatment with statins, have a cardiovascular risk comparable with that of FRS-matched subjects not treated with statins. If confirmed, this observation has an important clinical implication. In fact, the Fastest-IMT max-progr may be used by physicians to identify, after only 15 months, those patients who need to be more aggressively treated.
Strengths and Limitations
The IMPROVE study has several strengths. First, it is the first extensive investigation of C-IMT change and risk of VEs among European individuals. Second, standardized methods were used across all recruitment units; of particular relevance is the tight control of the methodology for image acquisition and measurement of C-IMT (all ultrasonographic scans were read blind in the same reading center). In addition, all sonographers involved in the study were trained and certified. Third, with 94.5% of individuals being included in follow-up, our results are likely to be minimally affected by loss to follow-up bias. Finally, analyses were adjusted for many potential VRFs and confounders, such as pharmacological treatments, and progression in different carotid segments was systematically computed and analyzed.
There are also several potential limitations: first, findings cannot be extended to the general European population or to subjects with <3 VRFs, and the IMPROVE subsets were neither random nor representative samples of the European population. Second, although participants were representative of subjects with ≥3 VRFs, systematic differences between recruiting centers might have occurred as previously explained. 17 Third, the assessment of VEs, being confined to symptomatic patients, may have underestimated the true event incidence. Fourth, images were obtained without taking into account the IMT changes because of the cardiac cycle; however, as our data fit very well with the average of IMT measurements obtained in peak systolic and end-diastolic phase, we think that it is unlikely that this methodological weakness may have affected our estimate of IMT progressions. Finally, because the Fastest-IMT max-progr was not a prespecified variable, the analyses conducted on this variable have to be considered as post hoc. Nevertheless, this was taken into account by applying an adequate Bonferroni correction.
Conclusions
This article describes a novel approach to measure C-IMT progression. The newly identified variable (Fastest-IMT max-progr ) reflects a focal increase of carotid IMT and is associated with cardiovascular risk. Although replication is needed in other large prospective studies before this variable is included in a new algorithm for risk assessment, the Fastest-IMT max-progr measure may be of clinical use in preventive decisions previously made solely on the basis of VRFs and an initial atherosclerosis profile.
